GSK's ofatumumab impresses in CLL trial
UK-based drug major GlaxoSmithKline says that data from a Phase I/II trial of its anti-CD20 monoclonal antibody, ofatumumab, has demonstrated the agent's anti-tumor activity in patients suffering from B-cell chronic lymphocytic leukemia. The findings, which are published in the February issue of the journal Blood, show that around half of the subjects in one of the three treatment groups achieved some degree of disease remission.
Ofatumumab, which is being developed by GSK in collaboration with Danish drugmaker Genmab (Marketletter January 1 and 8, 2007), targets a small region of the CD20 protein found on the surface the B-lymphocyte. Since the molecule is expressed on the surface of cancerous B-cells, the drug is thought to have potential application in a wide range of diseases.
62% of patients show objective response
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze